{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:54:08Z","timestamp":1789430048126,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.<\/jats:p>","DOI":"10.3390\/pharmaceutics16101287","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T03:57:52Z","timestamp":1727755072000},"page":"1287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-6362","authenticated-orcid":false,"given":"Roya","family":"Mohammadi-Meyabadi","sequence":"first","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"},{"name":"Institut de Nanoci\u00e8ncia i Nanotecnologia, Universitat de Barcelona (UB), Av. Diagonal 645, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-8459","authenticated-orcid":false,"given":"Mireia","family":"Mallandrich","sequence":"additional","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"},{"name":"Institut de Nanoci\u00e8ncia i Nanotecnologia, Universitat de Barcelona (UB), Av. Diagonal 645, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-5406","authenticated-orcid":false,"given":"Negar","family":"Beirampour","sequence":"additional","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-2066","authenticated-orcid":false,"given":"N\u00faria","family":"Garr\u00f3s","sequence":"additional","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"},{"name":"Institut de Nanoci\u00e8ncia i Nanotecnologia, Universitat de Barcelona (UB), Av. Diagonal 645, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-5622","authenticated-orcid":false,"given":"Lupe Carolina","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica y Ciencias Exactas, Universidad T\u00e9cnica Particular de Loja, Loja 1101608, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Sosa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Technology Research Group, Faculty of Chemical Sciences and Pharmacy, National Autonomous University of Honduras (UNAH), Tegucigalpa 11101, Honduras"},{"name":"Instituto de Investigaciones en Microbiolog\u00eda (IIM), Universidad Nacional Aut\u00f3noma de Hondura (UNAH), Tegucigalpa 11101, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-187X","authenticated-orcid":false,"given":"Joaquim","family":"Su\u00f1er-Carb\u00f3","sequence":"additional","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"},{"name":"Institut de Nanoci\u00e8ncia i Nanotecnologia, Universitat de Barcelona (UB), Av. Diagonal 645, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-8250","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Rodr\u00edguez-Lagunas","sequence":"additional","affiliation":[{"name":"Departament de Bioqu\u00edmica i Fisiologia, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 08028 Barcelona, Spain"},{"name":"Nutrition and Food Safety Research Institute (INSA-UB), 08921 Santa Coloma de Gramenet, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-5587","authenticated-orcid":false,"given":"Mar\u00eda Luisa","family":"Gardu\u00f1o-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Qu\u00edmicas, Instituto de Investigaci\u00f3n en Ciencias B\u00e1sicas y Aplicadas, Universidad Aut\u00f3noma del Estado de Morelos, Av. Universidad 1001, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-4821","authenticated-orcid":false,"given":"Ana C.","family":"Calpena-Campmany","sequence":"additional","affiliation":[{"name":"Departament de Farm\u00e0cia i Tecnologia Farmac\u00e8utica, i Fisicoqu\u00edmica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain"},{"name":"Institut de Nanoci\u00e8ncia i Nanotecnologia, Universitat de Barcelona (UB), Av. Diagonal 645, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The Psychosocial Burden of Psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"S\u0142uczanowska-G\u0142\u0105bowska, S., Ziegler-Krawczyk, A., Szumilas, K., and Pawlik, A. (2021). Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194307"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Silva-Abreu, M., Sosa, L., Espinoza, L.C., F\u00e1brega, M.-J., Rodr\u00edguez-Lagunas, M.J., Mallandrich, M., Calpena, A.C., Gardu\u00f1o-Ram\u00edrez, M.L., and Rinc\u00f3n, M. (2023). Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102403"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Psoriasis: A Phase 2b Randomized Placebo-Controlled Dose-Ranging Study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and Safety of the Janus Kinase 1 Inhibitor PF-04965842 in Patients with Moderate-to-Severe Psoriasis: Phase II, Randomized, Double-Blind, Placebo-Controlled Study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A Randomized Phase 2b Trial of Baricitinib, an Oral Janus Kinase (JAK) 1\/JAK2 Inhibitor, in Patients with Moderate-to-severe Psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ad.2023.09.005","article-title":"Roflumilast T\u00f3pico y Oral En Dermatolog\u00eda. Una Revisi\u00f3n Narrativa","volume":"115","author":"Gimeno","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"(2023, November 25). Eli Lilly and Company Olumiant (Baricitinib) Tablets 4 Mg, 2 Mg, 1 Mg. Available online: https:\/\/olumiant.lilly.com\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.molpharmaceut.0c00154","article-title":"Nanodelivery Systems for Topical Management of Skin Disorders","volume":"18","author":"Cui","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ajps.2017.07.004","article-title":"Film Forming Systems for Topical and Transdermal Drug Delivery","volume":"12","author":"Kathe","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"124376","DOI":"10.1016\/j.ijpharm.2024.124376","article-title":"Therapeutic Potential of Limonene-Based Syringic Acid Nanoemulsion: Enhanced Ex-Vivo Cutaneous Deposition and Clinical Anti-Psoriatic Efficacy","volume":"660","author":"Assalem","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kurebayashi, A.K., Phan, K., Abdoh, A., Andreo-Filho, N., Lopes, P.S., Mohammed, Y., and Leite-Silva, V.R. (2024). Strategic Approaches in Formulation Development for Atopic Dermatitis. Cosmetics, 11.","DOI":"10.3390\/cosmetics11040113"},{"key":"ref_21","first-page":"70","article-title":"F\u00f3rmulas dermatol\u00f3gicas","volume":"Volume 17","year":"2003","journal-title":"Farmacia Profesional: Econom\u00eda y Gesti\u00f3n"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mohammadi-Meyabadi, R., Beirampour, N., Garr\u00f3s, N., Alvarado, H.L., Lim\u00f3n, D., Silva-Abreu, M., Calpena, A.C., and Mallandrich, M. (2022). Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122714"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123732","DOI":"10.1016\/j.ijpharm.2023.123732","article-title":"Semi-Solid Functionalized Nanostructured Lipid Carriers Loading Thymol for Skin Disorders","volume":"651","author":"Folle","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpb.2015.01.026","article-title":"Biopharmaceutical Profile of Pranoprofen-Loaded PLGA Nanoparticles Containing Hydrogels for Ocular Administration","volume":"95","author":"Abrego","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1\/2 Inhibitor, in Healthy Volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.fct.2014.06.028","article-title":"A Review of the Nonclinical Safety of Transcutol\u00ae, a Highly Purified Form of Diethylene Glycol Monoethyl Ether (DEGEE) Used as a Pharmaceutical Excipient","volume":"72","author":"Sullivan","year":"2014","journal-title":"Food Chem. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1439-0507.2012.02202.x","article-title":"Evaluation of Novel Nystatin Nanoemulsion for Skin Candidosis Infections","volume":"56","year":"2013","journal-title":"Mycoses"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sosa, L., Calpena, A., Silva-Abreu, M., Espinoza, L., Rinc\u00f3n, M., Bozal, N., Domenech, O., Rodr\u00edguez-Lagunas, M., and Clares, B. (2019). Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070312"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ahmadi, N., Rinc\u00f3n, M., Silva-Abreu, M., Sosa, L., Pesantez-Narvaez, J., Calpena, A.C., Rodr\u00edguez-Lagunas, M.J., and Mallandrich, M. (2023). Semi-Solid Dosage Forms Containing Pranoprofen-Loaded NLC as Topical Therapy for Local Inflammation: In Vitro, Ex Vivo and In Vivo Evaluation. Gels, 9.","DOI":"10.3390\/gels9060448"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Latif, M.S., Nawaz, A., Asmari, M., Uddin, J., Ullah, H., and Ahmad, S. (2022). Formulation Development and In Vitro\/In Vivo Characterization of Methotrexate-Loaded Nanoemulsion Gel Formulations for Enhanced Topical Delivery. Gels, 9.","DOI":"10.3390\/gels9010003"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vlad, R.-A., Dudici, T.-C., Syed, M.A., Antonoaea, P., R\u00e9dai, E.M., Todoran, N., Cotoi, C.-T., B\u00eersan, M., and Ciurba, A. (2024). Impact of the Preparation Method on the Formulation Properties of Allantoin Hydrogels: Evaluation Using Semi-Solid Control Diagram (SSCD) Principles. Gels, 10.","DOI":"10.3390\/gels10010058"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106665","DOI":"10.1016\/j.ejps.2023.106665","article-title":"Formulation Development of Pharmaceutical Nanoemulgel for Transdermal Delivery of Feboxostat: Physical Characterization and in Vivo Evaluation","volume":"195","author":"Khan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rinphs.2014.09.003","article-title":"Evaluation of Formulation Properties and Skin Penetration in the Same Additive-Containing Formulation","volume":"4","author":"Inoue","year":"2014","journal-title":"Results Pharma Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0928-0987(01)00181-6","article-title":"In Vitro Permeation Profile of a Local Anaesthetic Compound from Topical Formulations with Different Rheological Behaviour\u2014Verified by in Vivo Efficacy Data","volume":"14","author":"Neelissen","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/03007995.2017.1352497","article-title":"Skin Penetration and Tissue Permeation after Topical Administration of Diclofenac","volume":"33","author":"Hagen","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/10717544.2014.935532","article-title":"Permeation Enhancer Strategies in Transdermal Drug Delivery","volume":"23","author":"Marwah","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"119655","DOI":"10.1016\/j.lfs.2021.119655","article-title":"Effect of Baricitinib on TPA-Induced Psoriasis like Skin Inflammation","volume":"279","year":"2021","journal-title":"Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/PTT.S126727","article-title":"Drug-Induced Psoriasis: Clinical Perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis Targets Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clindermatol.2011.08.015","article-title":"Effect of Moisturizers on Epidermal Barrier Function","volume":"30","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3121\/cmr.2017.1363","article-title":"The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review","volume":"15","author":"Purnamawati","year":"2017","journal-title":"Clin. Med. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pober, J.S., and Sessa, W.C. (2015). Inflammation and the Blood Microvascular System. Cold Spring Harb. Perspect. Biol., 7.","DOI":"10.1101\/cshperspect.a016345"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.ant.2018.10.001","article-title":"Chapter Six\u2013Overview of Peripheral and Central Inflammatory Responses and Their Contribution to Neurotoxicity","volume":"Volume 3","author":"Aschner","year":"2019","journal-title":"Advances in Neurotoxicology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1159\/000538993","article-title":"Challenges in Psoriasis Research: A Systematic Review of Preclinical Models","volume":"240","year":"2024","journal-title":"Dermatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nano.2019.03.017","article-title":"Nanoemulsion Strategy of Pioglitazone for the Treatment of Skin Inflammatory Diseases","volume":"19","author":"Espinoza","year":"2019","journal-title":"Nanomedicine"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/10\/1287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:08:16Z","timestamp":1760112496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/10\/1287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["pharmaceutics16101287"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16101287","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}